<code id='83E5A1B065'></code><style id='83E5A1B065'></style>
    • <acronym id='83E5A1B065'></acronym>
      <center id='83E5A1B065'><center id='83E5A1B065'><tfoot id='83E5A1B065'></tfoot></center><abbr id='83E5A1B065'><dir id='83E5A1B065'><tfoot id='83E5A1B065'></tfoot><noframes id='83E5A1B065'>

    • <optgroup id='83E5A1B065'><strike id='83E5A1B065'><sup id='83E5A1B065'></sup></strike><code id='83E5A1B065'></code></optgroup>
        1. <b id='83E5A1B065'><label id='83E5A1B065'><select id='83E5A1B065'><dt id='83E5A1B065'><span id='83E5A1B065'></span></dt></select></label></b><u id='83E5A1B065'></u>
          <i id='83E5A1B065'><strike id='83E5A1B065'><tt id='83E5A1B065'><pre id='83E5A1B065'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:75168
          Adam's take main illustration
          Molly Ferguson/STAT

          Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

          Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

          advertisement

          Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Ohio train derailment: Experts on toxic chemical risks
          Ohio train derailment: Experts on toxic chemical risks

          AblackplumerisesoverEastPalestine,Ohio,asaresultofacontrolleddetonationofaportionofthederailedNorfol

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze